Pet Pharm Biotech Co (ROCO:7762) COGS-to-Revenue : 0.46 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co COGS-to-Revenue?

Pet Pharm Biotech Co's Cost of Goods Sold for the six months ended in Dec. 2024 was NT$34.0 Mil. Its Revenue for the six months ended in Dec. 2024 was NT$74.8 Mil.

Pet Pharm Biotech Co's COGS to Revenue for the six months ended in Dec. 2024 was 0.46.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Pet Pharm Biotech Co's Gross Margin % for the six months ended in Dec. 2024 was 54.48%.

Pet Pharm Biotech Co COGS-to-Revenue Historical Data

The historical data trend for Pet Pharm Biotech Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co COGS-to-Revenue Chart

Pet Pharm Biotech Co Annual Data

Trend

Dec22

Dec23

Dec24

COGS-to-Revenue

0.53

0.45

0.46

Pet Pharm Biotech Co Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	-	0.49	0.42	0.48	0.46

Pet Pharm Biotech Co COGS-to-Revenue Calculation

Pet Pharm Biotech Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	60.736	/	130.7
	=	0.46

Pet Pharm Biotech Co's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	34.032	/	74.764
	=	0.46

Pet Pharm Biotech Co (ROCO:7762) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Pet Pharm Biotech Co's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	34.032 / 74.764
	=	54.48 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Pet Pharm Biotech Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pet Pharm Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051

Website

https://www.petpharmbio.com

Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines